BILLERICA, Mass.--(BUSINESS WIRE)--Millipore Corporation (NYSE:MIL), a life science leader that provides technologies, tools and services for bioscience research and biopharmaceutical manufacturing, today announced an expansion of its agreement with Novo Nordisk (NYSE: NVO) the world’s leading diabetes care company, to provide the biopharmaceutical market with recombinant human insulin, a key cell culture supplement used to manufacture biologic drugs.
